应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02359 药明康德
已收盘 04-30 16:08:06
35.450
-0.850
-2.34%
最高
37.000
最低
35.150
成交量
899.01万
今开
37.000
昨收
36.300
日振幅
5.10%
总市值
1,040亿
流通市值
137.22亿
总股本
29.33亿
成交额
3.21亿
换手率
2.32%
流通股本
3.87亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
药明康德(02359)下跌2.07%,报35.55元/股
金融界 · 43分钟前
药明康德(02359)下跌2.07%,报35.55元/股
《大行》野村:药明康德(02359.HK)首季业绩符预期 维持今年指引
阿斯达克财经 · 54分钟前
《大行》野村:药明康德(02359.HK)首季业绩符预期 维持今年指引
《大行》里昂降药明康德(02359.HK)目标价至42元 评级“跑赢大市”
阿斯达克财经 · 55分钟前
《大行》里昂降药明康德(02359.HK)目标价至42元 评级“跑赢大市”
药明康德:GLP-1大订单是长期合同,正计划扩建新产能
澎湃新闻 · 14:30
药明康德:GLP-1大订单是长期合同,正计划扩建新产能
公募调仓:立讯精密、药明康德退出持仓市值前十
21世纪经济报道 · 13:04
公募调仓:立讯精密、药明康德退出持仓市值前十
药明康德最新回应!事关客单、多肽产能等
中证网 · 11:57
药明康德最新回应!事关客单、多肽产能等
瑞银:维持药明康德(02359)“中性”评级 目标价降至40.1港元
智通财经 · 11:26
瑞银:维持药明康德(02359)“中性”评级 目标价降至40.1港元
药明康德:GLP-1大订单均属于长期合同
澎湃新闻 · 10:58
药明康德:GLP-1大订单均属于长期合同
药明康德:扣除新冠业务后,CDMO收入全年预期实现双位数增长
澎湃新闻 · 10:58
药明康德:扣除新冠业务后,CDMO收入全年预期实现双位数增长
《大行》瑞银降药明康德(02359.HK)目标价至40.1元 首季业绩逊 全年目标不变
阿斯达克财经 · 10:28
《大行》瑞银降药明康德(02359.HK)目标价至40.1元 首季业绩逊 全年目标不变
药明康德(02359.HK):首季新增逾300客户 欧美地区占四成
阿斯达克财经 · 10:23
药明康德(02359.HK):首季新增逾300客户 欧美地区占四成
药明康德再一次证明自己!一季度新增客户300+,CDMO分子数保持强劲增长
挖贝网 · 10:14
药明康德再一次证明自己!一季度新增客户300+,CDMO分子数保持强劲增长
药明康德:多肽需求强劲 22000升多肽新产能正进行工艺验证
南方财经网 · 10:10
药明康德:多肽需求强劲 22000升多肽新产能正进行工艺验证
药明康德:没有出现大量客户取消订单情况 一季度新增300多客户欧美占40%
南方财经网 · 10:04
药明康德:没有出现大量客户取消订单情况 一季度新增300多客户欧美占40%
药明康德一季度目标达成,恒生医药ETF(159892)连涨6日
每日经济新闻 · 10:01
药明康德一季度目标达成,恒生医药ETF(159892)连涨6日
图解药明康德一季报:第一季度单季净利润同比减10.42%
证券之星 · 02:21
图解药明康德一季报:第一季度单季净利润同比减10.42%
《蓝筹》药明康德(02359.HK)首季净利润19.42亿人民币 倒退10.4%
阿斯达克财经 · 01:47
《蓝筹》药明康德(02359.HK)首季净利润19.42亿人民币 倒退10.4%
【港股通】药明康德(02359)首季溢利19.42亿元人民币 同比减少10.42%
金吾财讯 · 04-29 23:06
【港股通】药明康德(02359)首季溢利19.42亿元人民币 同比减少10.42%
药明康德(603259.SH)发布一季度业绩,净利润19.42亿元,同比下降10.42%
智通财经 · 04-29 22:57
药明康德(603259.SH)发布一季度业绩,净利润19.42亿元,同比下降10.42%
药明康德一季度营收净利双降 称如期达成设定目标
澎湃新闻 · 04-29 22:50
药明康德一季度营收净利双降 称如期达成设定目标
公司概况
公司名称:
药明康德
所属市场:
SEHK
上市日期:
--
主营业务:
无锡药明康德新药开发股份有限公司是一家主要提供新药研发、生产与配套服务以及相关技术平台服务的中国投资控股公司。该公司主要发现、研发及生产小分子药物、细胞疗法及基因疗法,以及提供医疗器械测试服务。该公司主要通过四个业务部门运营,包括中国区实验室服务部门、合约生产组织/合约研发及生产组织服务(CMO/CDMO服务)部门、美国区实验室服务部门以及临床研究服务部门。
发行价格:
--
{"stockData":{"symbol":"02359","market":"HK","secType":"STK","nameCN":"药明康德","latestPrice":35.45,"timestamp":1714464486031,"preClose":36.3,"halted":0,"volume":8990058,"delay":0,"floatShares":387076150,"shares":2933336997,"eps":3.5264094,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.85,"latestTime":"04-30 16:08:06","open":37,"high":37,"low":35.15,"amount":320800700,"amplitude":0.050964,"askPrice":35.5,"askSize":200,"bidPrice":35.45,"bidSize":2800,"shortable":3,"etf":0,"ttmEps":3.494057030235723,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714613400000},"adr":0,"listingDate":1544630400000,"adjPreClose":36.3,"dividendRate":0.029983,"openAndCloseTimeList":[[1714440600000,1714449600000],[1714453200000,1714464000000]],"volumeRatio":1.27108,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603259","market":"SH","secType":"STK","nameCN":"药明康德","latestPrice":43.67,"timestamp":1714460400000,"preClose":44.57,"halted":0,"volume":80698597,"delay":0,"premium":"-24.73"}},"requestUrl":"/m/hq/s/02359/wiki","defaultTab":"wiki","newsList":[{"id":"2431629783","title":"药明康德(02359)下跌2.07%,报35.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431629783","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431629783?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:57","pubTimestamp":1714463824,"startTime":"0","endTime":"0","summary":"4月30日,药明康德盘中下跌2.07%,截至15:57,报35.55元/股,成交3.05亿元。至2022年,公司已与全球30多个国家的6000多家合作伙伴开展研发创新项目,被MSCI评为ESGAA级,致力于实现“让天下没有难做的药,难治的病”的愿景。截至2024年一季报,药明康德营业总收入79.82亿元、净利润19.42亿元。4月29日,公司以每股42.95-45.01人民币回购45.21万股,回购金额2005万人民币。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/30155740493474.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431036714","title":"《大行》野村:药明康德(02359.HK)首季业绩符预期 维持今年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2431036714","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431036714?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:46","pubTimestamp":1714463160,"startTime":"0","endTime":"0","summary":"野村发表研报指,药明康德(02359.HK) 今年首季业绩表现符合预期,收入按年跌11%,盈利按年跌10%。由于销售开支比率提升0.3个百分点至2.2%,拖累期内经营溢利率下降2.1个百分点至24%,毛利率亦收窄至37.3%。管理层仍维持2024年业绩指引不变,野村目前对药明康德的投资评级为“买入”,目标价54.56元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 12:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205150919126_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205150919126_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346484/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431528364","title":"《大行》里昂降药明康德(02359.HK)目标价至42元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2431528364","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431528364?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:45","pubTimestamp":1714463100,"startTime":"0","endTime":"0","summary":"里昂发表报告指,药明康德(02359.HK) 第一季收入按年下降11%,非新冠药收入按年下降1.8%,低于公司对全年非新冠药增长2.7%至8.6%的指引。经调整非国际财务报告准则净利润按年下降18%,低于公司 对全年经调整non-IFRS净利润率持平的指引。里昂指,药明康德维持2024年指引目标。该行则将2024至2026年的收入和净利润预测下调2至3%,并将港股目标价由46元下调至42元,但维持“跑赢大市 ”评级。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 12:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220419153916103_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220419153916103_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346470/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431542713","title":"药明康德:GLP-1大订单是长期合同,正计划扩建新产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2431542713","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431542713?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:30","pubTimestamp":1714458638,"startTime":"0","endTime":"0","summary":"刚刚发布一季报的药明康德在业绩会上回应GLP-1订单、欧美客户数量、CDMO业务增速等多个问题。4月30日,药明康德在2024年一季度业绩会上表示,公司GLP-1大订单都是长期合同,一季度末TIDES在手订单同比增长110%,继续保持强劲增长,同时正在计划扩建新的产能。自今年1月底起,药明康德卷入美国生物安全法案风波。4月30日,药明康德A股盘中一度跌超2%,截至午盘跌2.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/jjxw/2024-04-30/doc-inatqwyz0593194.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-04-30/doc-inatqwyz0593194.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431301963","title":"公募调仓:立讯精密、药明康德退出持仓市值前十","url":"https://stock-news.laohu8.com/highlight/detail?id=2431301963","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2431301963?lang=zh_cn&edition=full","pubTime":"2024-04-30 13:04","pubTimestamp":1714453440,"startTime":"0","endTime":"0","summary":"公募基金一季报披露完毕,基金调仓浮出水面。贵州茅台以 640.60 亿元的持仓市值保持第一。新进前十大重仓公司为紫金矿业和美的集团,而立讯精密和药明康德退出前十大。此外,较多主动权益基金减持了立讯精密、药明康德和智飞生物,持仓基金数量分别减少193、181、137只。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301312597a579b7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301312597a579b7b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431331355","title":"药明康德最新回应!事关客单、多肽产能等","url":"https://stock-news.laohu8.com/highlight/detail?id=2431331355","media":"中证网","top":-1,"share":"https://www.laohu8.com/m/news/2431331355?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:57","pubTimestamp":1714449420,"startTime":"0","endTime":"0","summary":"4月30日,中国证券报·中证金牛座记者获悉,药明康德人士在药明康德一季度业绩会上透露,今年1月份,22000升的多肽新产能已全部投入使用。此外,由于市场对多肽的需求非常强劲,所以公司目前正计划在泰兴扩建新的多肽产能。同时,药明康德表示,从第一季度的数据来看,没有出现客户大量取消订单的情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043012021987c20a81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043012021987c20a81&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431633840","title":"瑞银:维持药明康德(02359)“中性”评级 目标价降至40.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431633840","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431633840?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:26","pubTimestamp":1714447568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,瑞银发布研究报告称,维持药明康德“中性”评级,基于首季业绩表现,将2024至2026年每股盈利预测下调4%、5%及5%,至3.47元、3.73元及3.99元人民币,目标价从44港元下调至40.1港元。管理层目前仍维持2024年度收入达383亿至405亿元人民币的目标不变,撇除COVID相关料全年收入将同比增长2.7%至8.6%,资本开支及自由现金流目标亦维持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116079.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431915382","title":"药明康德:GLP-1大订单均属于长期合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2431915382","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431915382?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:58","pubTimestamp":1714445880,"startTime":"0","endTime":"0","summary":"4月30日,药明康德于业绩交流会上表示,公司GLP-1大订单都是长期合同。一季度末TIDES 业务(主要为寡核苷酸和多肽)在手订单同比增长110%,继续保持强劲增长,同时正在计划扩建新的产能。(澎湃新闻记者 李潇潇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301059318b6469f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301059318b6469f7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431382676","title":"药明康德:扣除新冠业务后,CDMO收入全年预期实现双位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2431382676","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431382676?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:58","pubTimestamp":1714445880,"startTime":"0","endTime":"0","summary":"4月30日,药明康德在业绩交流会上表示,公司CDMO项目交付节奏在不同季度之间经常有波动,不用特别关注一个季度的变化。一季度收入增速放缓,主要还是由于CDMO业务是基于交付确认收入。尽管项目都在正在执行中,但后期项目的交付节奏和交付项目大小都有差异,收入在季度之间容易产生较大波动。之后季度的收入将逐步爬升。CDMO业务收入全年预期实现扣除新冠双位数增长。(澎湃新闻记者 李潇潇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301059288b6469e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301059288b6469e2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431381079","title":"《大行》瑞银降药明康德(02359.HK)目标价至40.1元 首季业绩逊 全年目标不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2431381079","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431381079?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:28","pubTimestamp":1714444080,"startTime":"0","endTime":"0","summary":"瑞银发表研究报告指,药明康德首季业绩表现逊色,收入按年下跌11%至79.8亿元人民币,低于该行预测的88.3亿元人民币及市场普遍预期的84.1亿元人民币;纯利下跌10.4%至19.4亿元人民币,同样低于瑞银及市场预测的21.3亿及20.4亿元人民币。管理层目前仍维持2024年度收入介乎383亿至405亿元人民币的目标不变,撇除COVID相关料全年收入将按年增长2.7%至8.6%,资本开支及自由现金流目标亦维持不变。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346242/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431386934","title":"药明康德(02359.HK):首季新增逾300客户 欧美地区占四成","url":"https://stock-news.laohu8.com/highlight/detail?id=2431386934","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431386934?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:23","pubTimestamp":1714443780,"startTime":"0","endTime":"0","summary":"药明康德(02359.HK) 在业绩会上表示,从第一季度的数据来看,没有出现客户大量取消订单的情况,只有极个别早期的研发客户因议案草案的扰动取消部分服务,公司客户群庞大,不同客户会基于自身的情况做出不同考虑。公司透露今年首季新增超过300个客户,当中约40%来自欧美地区,中国新增客户接近50%,其他地区占比10%,从收入贡献来讲,欧美客户的收入贡献占比更大。(su/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-29 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20181129150541971_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20181129150541971_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1346232&catg=4&source=AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431385717","title":"药明康德再一次证明自己!一季度新增客户300+,CDMO分子数保持强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2431385717","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2431385717?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:14","pubTimestamp":1714443258,"startTime":"0","endTime":"0","summary":"前期受美国拟议法案影响的药明康德发布了2024年的第一份业绩报告,该公司表示在外部环境挑战下,第一季度达成目标,保持稳健经营态势。药明康德一季度实现营收79.82亿元,剔除新冠商业化项目同比下降1.8%,归母净利润19.42亿元,经调整non-IFRS归母净利润19.13亿元,自由现金流持续为正。一季度药明康德新增客户依旧超过 300家,与去年超过310家相差无几。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431385536","title":"药明康德:多肽需求强劲 22000升多肽新产能正进行工艺验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2431385536","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431385536?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:10","pubTimestamp":1714443036,"startTime":"0","endTime":"0","summary":"南方财经4月30日电,据财联社,在今日的药明康德一季度业绩会上,药明康德方面人士透露,今年1月份22000升的多肽新产能已全部投入使用,这部分新产能现正进行PPQ工艺验证批次,验证完毕即进入正式商业化生产;公司TIDES业务第一季度增长了43%,一季度末在手订单同比增长110%。此外,由于市场对多肽的需求非常强劲,所以公司目前正计划在泰兴扩建新的多肽产能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404303065234095.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431386159","title":"药明康德:没有出现大量客户取消订单情况 一季度新增300多客户欧美占40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431386159","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431386159?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:04","pubTimestamp":1714442645,"startTime":"0","endTime":"0","summary":"据财联社,在今日药明康德一季度业绩会上,药明康德方面表示,从第一季度的数据来看,没有出现客户大量取消订单的情况,只有极个别早期的研发客户,因为议案草案的扰动取消了部分服务,公司有着庞大客户群,不同客户会基于自身的情况做出不同考虑;一季度300多个新增客户来自欧美地区的占比在40%左右,中国新增客户将近50%左右,其他地区还有10%,从收入贡献上来讲,欧美客户的收入贡献占比更大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404303065213915.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431385742","title":"药明康德一季度目标达成,恒生医药ETF(159892)连涨6日","url":"https://stock-news.laohu8.com/highlight/detail?id=2431385742","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431385742?lang=zh_cn&edition=full","pubTime":"2024-04-30 10:01","pubTimestamp":1714442460,"startTime":"0","endTime":"0","summary":"自4月22日(上周一)起,港股市场持续强势,恒生医药ETF(159892)连涨6日,累计涨幅超13%。截至昨日,药明康德港股已连续2日上涨。药明康德发布2024年一季度业绩报告,在外部环境挑战下,药明康德一季度目标达成,其一季度营收达79.8亿元,归母净利润达19.4亿元。此外,药明康德近期持续的回购动作同样值得关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301003217a578b94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301003217a578b94&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431980848","title":"图解药明康德一季报:第一季度单季净利润同比减10.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431980848","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431980848?lang=zh_cn&edition=full","pubTime":"2024-04-30 02:21","pubTimestamp":1714414912,"startTime":"0","endTime":"0","summary":"证券之星消息,药明康德2024年一季报显示,公司主营收入79.82亿元,同比下降10.95%;归母净利润19.42亿元,同比下降10.42%;扣非净利润20.34亿元,同比上升8.86%;负债率25.21%,投资收益-892.51万元,财务费用-4.24亿元,毛利率38.13%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300222038b631a5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300222038b631a5f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431781451","title":"《蓝筹》药明康德(02359.HK)首季净利润19.42亿人民币 倒退10.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431781451","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431781451?lang=zh_cn&edition=full","pubTime":"2024-04-30 01:47","pubTimestamp":1714412820,"startTime":"0","endTime":"0","summary":"药明康德(02359.HK) 公布3月止第一季度报告,实现营业收入79.82亿人民币(下同),按年下降11%;毛利30.06亿元,下跌14.7%。归属股东净利润19.42亿元,倒退10.4%,每股收益67分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-29 16:25。)过往派息公布日期派息事项派息内容2024/03/18末期业绩普通股息:人民币 0.983362023/10/30第三季业绩无派息2023/07/31中期业绩无派息2023/04/24第一季业绩无派息 AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220419153917927_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220419153917927_s.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346088/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431989893","title":"【港股通】药明康德(02359)首季溢利19.42亿元人民币 同比减少10.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431989893","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2431989893?lang=zh_cn&edition=full","pubTime":"2024-04-29 23:06","pubTimestamp":1714403218,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明康德(02359)公布,于2024年第一季度,公司归属于上市公司股东的净利润19.42亿元(人民币,下同),同比减少10.42%;基本每股收益0.67元。同期,录得营业收入79.82亿元,同比减少10.95%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210611/OWUzZDUxMTYyMzQxNDA5ODI1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210611/OWUzZDUxMTYyMzQxNDA5ODI1OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936018","is_publish_highlight":false,"gpt_icon":0},{"id":"2431898607","title":"药明康德(603259.SH)发布一季度业绩,净利润19.42亿元,同比下降10.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431898607","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431898607?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:57","pubTimestamp":1714402633,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药明康德(603259.SH)披露2024年第一季度报告,报告期公司实现营收79.82亿元,同比下降10.95%;归母净利润19.42亿元,同比下降10.42%;扣非净利润20.34 亿元,同比增长7.3%。基本每股收益0.67元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115399.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431889875","title":"药明康德一季度营收净利双降 称如期达成设定目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2431889875","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431889875?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:50","pubTimestamp":1714402252,"startTime":"0","endTime":"0","summary":"药明康德一季度营收净利双降 称如期达成设定目标","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404293064194034.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404293064194034.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxiapptec.com.cn","stockEarnings":[{"period":"1week","weight":0.0885},{"period":"1month","weight":-0.0216},{"period":"3month","weight":-0.3552},{"period":"6month","weight":-0.6069},{"period":"1year","weight":-0.4634},{"period":"ytd","weight":-0.5431}],"compareEarnings":[{"period":"1week","weight":0.0748},{"period":"1month","weight":0.0729},{"period":"3month","weight":0.1301},{"period":"6month","weight":0.0377},{"period":"1year","weight":-0.108},{"period":"ytd","weight":0.041}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"无锡药明康德新药开发股份有限公司是一家主要提供新药研发、生产与配套服务以及相关技术平台服务的中国投资控股公司。该公司主要发现、研发及生产小分子药物、细胞疗法及基因疗法,以及提供医疗器械测试服务。该公司主要通过四个业务部门运营,包括中国区实验室服务部门、合约生产组织/合约研发及生产组织服务(CMO/CDMO服务)部门、美国区实验室服务部门以及临床研究服务部门。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018355},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.020248},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.039874},{"month":4,"riseRate":0.5,"avgChangeRate":0.008046},{"month":5,"riseRate":0.4,"avgChangeRate":-0.027282},{"month":6,"riseRate":0.8,"avgChangeRate":0.101299},{"month":7,"riseRate":0.6,"avgChangeRate":0.050449},{"month":8,"riseRate":0.4,"avgChangeRate":0.041019},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015832},{"month":10,"riseRate":0.6,"avgChangeRate":0.02437},{"month":11,"riseRate":0.4,"avgChangeRate":0.027502},{"month":12,"riseRate":0.6,"avgChangeRate":0.018311}],"exchange":"SEHK","name":"药明康德","nameEN":"WUXI APPTEC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明康德(02359)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明康德(02359)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明康德,02359,药明康德股票,药明康德股票老虎,药明康德股票老虎国际,药明康德行情,药明康德股票行情,药明康德股价,药明康德股市,药明康德股票价格,药明康德股票交易,药明康德股票购买,药明康德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明康德(02359)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明康德(02359)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}